The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Small cell carcinoma of the prostate
Open accessAbstract
Pure small-cell carcinoma (SCC) of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Histologically, prostatic SCCs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to SCCs of the lungs. In most cases, SCC of the prostate is associated with conventional prostatic adenocarcinoma. Both components of these mixed tumours frequently share molecular alterations such as ERG gene rearrangements or AURKA and MYCN amplifications, suggesting a common clonal origin. The clinical behaviour of small-cell prostate carcinomas is characterized by extensive local disease, visceral disease, and low PSA levels despite large metastatic burden. Commonly, the emergence of the SCC occurs in patients with high-grade adenocarcinoma who are often treated with androgen deprivation treatment (ADT). However, SCCs do not usually benefit from ADT. A biopsy of accessible lesions is strongly recommended to identify those with SCC pathological features, as management is undoubtedly affected by this finding. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Aupérin, A., Arriagada, R., Pignon, J.-P., Le Péchoux, C., Gregor, A., Stephens, R. J., Kristjansen, P. E. G., Johnson, B. E., Ueoka, H., Wagner, H., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410703 · Cited by 1,718
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0130 · Cited by 999
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Bonkhoff, H., & Remberger, K. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199602)28:2<98::aid-pros4>3.0.co;2-j · Cited by 416
Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases
Wang, W., & Epstein, J. I. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318058a96b · Cited by 375
Self-citationPapandreou, C. N., Daliani, D. D., Thall, P. F., Tu, S.-M., Wang, X., Reyes, A., Troncoso, P., & Logothetis, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.065 · Cited by 286
Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases
Tětu, B., Ro, J. Y., Ayala, A. G., Johnson, D. E., Logothetis, C. J., & Ordonez, N. G. (1987) · Cancer · doi:10.1002/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x · Cited by 278
Mosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., Perner, S., Bismar, T. A., Erbersdobler, A., Dhir, R., et al. (2013) · Neoplasia · doi:10.1593/neo.121550 · Cited by 249
Neuroendocrine cells in tumour growth of the prostate.
Abrahamsson, P. A. (1999) · Endocrine-related cancer · doi:10.1677/erc.0.0060503 · Cited by 247
ERG gene rearrangements are common in prostatic small cell carcinomas
Lotan, T. L., Gupta, N. S., Wang, W., Toubaji, A., Haffner, M. C., Chaux, A., Hicks, J. L., Meeker, A. K., Bieberich, C. J., De Marzo, A. M., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.7 · Cited by 218
Self-citationAprikian, A. G., Cardon‐Cardo, C., Fair, W. R., & Reuter, V. E. (1993) · Cancer · doi:10.1002/1097-0142(19930615)71:12<3952::aid-cncr2820711226>3.0.co;2-x · Cited by 207
Small Cell Carcinoma of the Prostate: An Immunohistochemical Study
Yao, J. L., Madeb, R., Bourne, P., Lei, J., Yang, X., Tickoo, S., Liu, Z., Tan, D., Cheng, L., Hatem, F., et al. (2006) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200606000-00005 · Cited by 206
Lapuk, A. V., Wu, C., Wyatt, A. W., McPherson, A., McConeghy, B. J., Brahmbhatt, S., Mo, F., Zoubeidi, A., Anderson, S., Bell, R. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4047 · Cited by 196
Oesterling, J. E., Hauzeur, C. G., & Farrow, G. M. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37390-1 · Cited by 192
Evans, A. J., Humphrey, P. A., Belani, J., van der Kwast, T. H., & Srigley, J. R. (2006) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200606000-00003 · Cited by 179
BURCHARDT, T., BURCHARDT, M., CHEN, M.-W., CAO, Y., DE LA TAILLE, A., SHABSIGH, A., HAYEK, O., DORAI, T., & BUTTYAN, R. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68241-9 · Cited by 170
Yuan, T.-C., Veeramani, S., Lin, F.-F., Kondrikou, D., Zelivianski, S., Igawa, T., Karan, D., Batra, S. K., & Lin, M.-F. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01043 · Cited by 169
Wright, M. E., Tsai, M.-J., & Aebersold, R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0031 · Cited by 166
Chemotherapy for Small Cell Carcinoma of Prostatic Origin
Amato, R. J., Logothetis, C. J., Hallinan, R., Ro, J. Y., Sella, A., & Dexeus, F. H. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37427-x · Cited by 164
Unusual and Underappreciated: Small Cell Carcinoma of the Prostate
Palmgren, J. S., Karavadia, S. S., & Wakefield, M. R. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.10.026 · Cited by 162
Neuro‐endocrine Cells—A New Prognostic Parameter in Prostate Cancer
Cohen, R. J., Glezerson, G., & HAFFEJEE, Z. (1991) · British Journal of Urology · doi:10.1111/j.1464-410x.1991.tb15318.x · Cited by 152
Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Tzelepi, V., Zhang, J., Lu, J.-F., Kleb, B., Wu, G., Wan, X., Hoang, A. G., Efstathiou, E., Sircar, K., Navone, N. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1867 · Cited by 152
Fléchon, A., Pouessel, D., Ferlay, C., Pérol, D., Beuzeboc, P., Gravis, G., Joly, F., Oudard, S. M., Deplanque, G., Zanetta, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr004 · Cited by 143
Williamson, S. R., Zhang, S., Yao, J. L., Huang, J., Antonio Lopez-beltran, B., Shen, S. S., Osunkoya, A. O., MacLennan, G. T., Montironi, R., & Liang Cheng, C. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.56 · Cited by 140
Mitosis as an anti-cancer target
Janssen, A., & Medema, R. H. (2011) · Oncogene · doi:10.1038/onc.2011.30 · Cited by 137
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor
Scheble, V. J., Braun, M., Beroukhim, R., Mermel, C. H., Ruiz, C. F., Wilbertz, T., Stiedl, A., Petersen, K., Reischl, M., Kuefer, R., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.87 · Cited by 129
TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate☆
Guo, C. C., Dancer, J. Y., Wang, Y., Aparicio, A. M., Navone, N. M., Troncoso, P., & Czerniak, B. A. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.026 · Cited by 116
Deorah, S., Rao, M. B., Raman, R., Gaitonde, K., & Donovan, J. F. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10523.x · Cited by 103
Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma
Han, B., Mehra, R., Suleman, K., Tomlins, S. A., Wang, L., Singhal, N., Linetzky, K. A., Palanisamy, N., Zhou, M., Chinnaiyan, A. M., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.79 · Cited by 99
Culine, S., Demery, M. E., Lamy, P., Iborra, F., Avancès, C., & Pinguet, F. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.044 · Cited by 96
Neuroendocrine Differentiation in Metastatic Prostatic Adenocarcinoma
Aprikian, A. G., Cordon‐Cardo, C., Fair, W. R., Zhang, Z., Bazinet, M., Hamdy, S. M., & Reuter, V. E. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)35121-2 · Cited by 95
Progression of prostate cancer to neuroendocrine cell tumor
Tanaka, M., Suzuki, Y., Takaoka, K., Suzuki, N., Murakami, S., Matsuzaki, O., & Shimazaki, J. (2001) · International Journal of Urology · doi:10.1046/j.1442-2042.2001.00347.x · Cited by 93
Helpap, B., Köllermann, J. W., & Oehler, U. (1999) · Urologia Internationalis · doi:10.1159/000030376 · Cited by 89
Molecular characterization of prostatic small‐cell neuroendocrine carcinoma
Clegg, N. J., Ferguson, C., True, L. D., Arnold, H., Moorman, A. J., Quinn, J. E., Vessella, R. L., & Nelson, P. S. (2003) · The Prostate · doi:10.1002/pros.10217 · Cited by 89
Loriot, Y., Massard, C., Gross‐Goupil, M., Palma, M. D., Escudier, B. J., Bossi, A., & Fizazi, K. S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn694 · Cited by 85
Hansel, D. E., Nakayama, M., Luo, J., Abukhdeir, A. M., Park, B. H., Bieberich, C. J., Hicks, J. L., Eisenberger, M. A., Nelson, W. G., Mostwin, J. L., et al. (2009) · The Prostate · doi:10.1002/pros.20910 · Cited by 78
Self-citationERG rearrangement in small cell prostatic and lung cancer
Scheble, V. J., Braun, M., Wilbertz, T., Stiedl, A., Petersen, K., Schilling, D., Reischl, M., Seitz, G., Fend, F., Kristiansen, G., et al. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03564.x · Cited by 66
Miyoshi, Y., Uemura, H., Kitami, K., Satomi, Y., Kubota, Y., & Hosaka, M. (2001) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.00936.x · Cited by 57
Schelling, L. A., Williamson, S. R., Zhang, S., Yao, J. L., Wang, M., Huang, J., Montironi, R., Antonio Lopez-beltran, B., Emerson, R. E., Idrees, M. T., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.05.005 · Cited by 50
Serum chromogranin‐A in advanced prostate cancer
Ferrero-Poüs, M., Hersant, A.-M., Pecking, A. P., Brésard‐Leroy, M., & Pichon, M.-F. (2001) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.001223.x · Cited by 38
Alshaikh, O. M., Almahfouz, A., Al‐Hindi, H., Mahfouz, A. B., & Alzahrani, A. S. (2010) · Endocrine Practice · doi:10.4158/ep09243.cr · Cited by 20
Cited by
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 502
Self-citationPlatinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Tan, H.-L., Sood, A., Rahimi, H. A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C. D., Epstein, J. I., Netto, G. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1982 · Cited by 346
Self-citationReprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
Park, J. W., Lee, J. K., Sheu, K. M., Wang, L., Balanis, N. G., Nguyen, K., Smith, B. A., Cheng, C., Tsai, B. L., Cheng, D., et al. (2018) · Science · doi:10.1126/science.aat5749 · Cited by 343
Metadata
- Authors
- Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I., & Eisenberger, M. A.
- Venue
- Nature Reviews Urology
- Published
- 2014-02-18
- Volume
- 11
- Issue
- 4
- Pages
- 213-219
- ISSN
- 1759-4812 (ISSN-L)
- 1759-4820
- OpenAlex
- W2068927098
- Cited by
- 276
- References
- 43
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.